Stock Update (NASDAQ:INSM): Insmed Incorporated Announces Upcoming Data Presentations at ERS 2015

Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported two ARIKAYCE™ (liposomal amikacin for inhalation) posters will be presented at the European Respiratory Society (ERS) International Congress taking place in Amsterdam from September 26-30.

Summarized below are the poster titles and presentation times.

Poster Title: Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
Lead Author: K. Olivier
Poster Number: PA371
Date: Sunday, September 27, 2015
Session Time: 08:30-10:30 AM
Session Title: Bronchiectasis and NTM infections: clinical aspects and research outlook

Poster Title: A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)
Lead Author: D. Griffith
Poster Number: PA3945
Date: Tuesday, September 29, 2015
Session Time: 12:50 PM-2:40 PM
Session Title: Novel strategies for the management of asthma, COPD and airway infections. (Original Source)

Shares of Insmed closed yesterday at $24.60. INSM has a 1-year high of $28.66 and a 1-year low of $12.17. The stock’s 50-day moving average is $25.50 and its 200-day moving average is $23.61.

Insmed Inc is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its products candidates includes ARIKAYCE.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts